Open multicentre trial of zuclopenthixol in mania and schizophrenia based on the AMDP scales.
A total of 95 schizophrenic or manic patients received zuclopenthixol (cis(Z)-clopenthixol) either intramuscularly or orally during a period of 2 to 4 weeks in mean daily doses of 25 mg (i.m.) or 75 mg (p.o.). They were rated with the CGI, VAS, MSS, BPRS, and AMDP scales. Zuclopenthixol proved to be a potent antimanic, anti-aggressive and antidelusional neuroleptic already from the second day of injection. Very few anticholinergic and extrapyramidal side effects as well as little somnolence were seen and the local tolerance was excellent. The 14-factor AMDP profile proved valid, sensitive to change and highly differentiated.
Bobon
D
D
Troisfontaines
B
B
Kempeneers
J L
JL
Xhenseval
B
B
Bourdouxhe
S
S
Mirel
J
J
Gilson
H
H
Toussaint
C
C
von Frenckell
R
R
Pedersen
V
V
D000284:Administration, Oral; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D003006:Clopenthixol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D051379:Mice; D011569:Psychiatric Status Rating Scales; D011817:Rabbits; D051381:Rats; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D013892:Thioxanthenes / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D013892:Thioxanthenes; D003006:Clopenthixol